Hsiao, Michael

MHsiao6x7Professor


Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-27871243

 

 

EDUCATION AND POSITIONS HELD:

  • D.V.M., National Taiwan University, 1983
  • Ph.D., Pathology, University of Southern California, 1991 Postdoctoral Fellow, University of California at San Diego, 1991–1993
  • Postgraduate Biochemist, University of California at San Diego, 1993–1994
  • Senior Research Associate, Stanford University, 1994–1998
  • Associate Investigator of Medical Education and Research, Kaohsiung Veterans General Hospital, 1998–2005
  • Adjunct Associate Professor of Veterinary Medicine, National Taiwan University, 1998-present
  • Associate Professor, Genomics Research Center, Academia Sinica, 2005-2015
  • Adjunct Associate Professor of Biology, National Defense Medical College, 2006-present
  • Professor, Genomics Research Center, Academia Sinica, 2015-present

HONORS:

  • National Cancer Institute Post-Doctoral Fellowship, 1991-1993
  • First Prize, Tumor Section, Congress for the Neurological Surgeons, 1997
  • Young Investigator Award, American Association for the Neurological Surgeons and Congress for Neurological Surgeons 1998
  • First prize, Taiwan Association for Veterinary Medicine, 1999
  • Second Prize, Asia-Pacific Congress on Oral cavity Cancer, 2008
  • Editorial Board, Am J Cancer Res, 2011
  • ad hoc reviewer for Ann Surg Oncol., BBA-Mol Cell Res, Brit J Cancer, Brit J Dermatol, Cancer, Cancer Gene Therapy, Cancer Lett., Clin Exp Metastas, Gene Ther, Gut, Histol Histopathol, Int J Cancer, J Biomed Biotech, J Cancer Mol, J Phys Chem C, Oncogene, Oral Oncol

RESEARCH INTERESTS:

  • Targeting tumor growth/survival pathways to enhance tumor chemosensitivity and/or radiosensitivity.
  • Novel strategies to overcome tumor metastasis
    • Novel microarray based gene discovery associated with tumor metastasis
    • Viral or pharmacological compounds based inhibition of PI3K/Akt pathway to inhibit tumor invasion and migration
    • Therapeutical interventions using tumor metastasis suppressor genes in preclinical trial settings
    • Establishment of novel real-time 3D quantifiable metastatic tumor models to investigate tumor metastasis dynamics and evaluate therapeutical efficacy
    • Utilization of high-throughput proteomic analysis for the identification of novel tumor metastasis markers and therapeutical evaluations.
  • Development of nanoparticle-mediated high-throughput transfection platforms to identify and characterize novel gene expression functional consequences.

SELECTED PUBLICATIONS:

  • Chan MH, Chan YC, Liu RS, Hsiao M*, 2020, “A Selective Drug Delivery System Based on Phospholipid-Type Nanobubbles for Lung Cancer Therapy”, Nanomedicine, In Press. (SCIE) (IF: 5.005; SCIE ranking: 34.8%,13.7%)
  • Lai TC, Fang CY, Jan YH, Hsieh HL, Liu JH, Chang MH, Hsiao M*, 2020, “Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway”, Cell Communication and Signaling, In Press. (SCIE) (IF: 5.324; SCIE ranking: 24.2%)
  • Fang CY, Lai TC, Hsiao M*, Chang YC, 2020, “The Diverse Roles of TAO Kinases in Health and Diseases [Invited Reviews]”, International Journal of Molecular Sciences, Oct 10; 21(20) 7463. (SCIE) (IF: 3.687; SCIE ranking: 30.7%,30.4%)
  • Chang YC, Chen MH, Yeh CN, Hsiao M*, 2020, “Omics-based Platforms: Current Status and Potential Use for Cholangiocarcinoma [Invited Reviews]”, Biomolecules, Sep 28; 10(10), 1377. (SCIE)
  • Yang YF, Chang YC, Jan YH, Yang CJ, Huang MS, Hsiao M*, 2020, “Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway”, Oncogenesis, Aug 29; 9(8):78. (SCIE) (IF: 4.722; SCIE ranking: 24.2%)
  • Fan CC, Tsai ST, Yang JC, Chang LC, Chen GY, Sher YP, Wang SC, Hsiao M*, Chang WC, 2020, “EFHD2 Contributes to Non-small Cell Lung Cancer Cisplatin Resistance by the Activation of NOX4-ROS-ABCC1 Axis”, Redox Biology, Jul; 34:101571. (SCIE) (IF: 7.126; SCIE ranking: 10.6%)
  • Chan MH, Huang WT, Wang J, Liu RS, Hsiao M*, 2020, “Next‐Generation Cancer‐Specific Hybrid Theranostic Nanomaterials: MAGE‐A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ Suppression of Lung Adenocarcinoma Growth and Metastasis”, Advanced Science, May 6; 7(9):1903741. (SCIE) (IF: 12.441; SCIE ranking: 7.6%,6%,8.7%)
  • Chang YC, Yang YF, Chiou J, Tsai HF, Fang CY, Yang CJ, Chen CL, Hsiao M*, 2020, “Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness”, Cell Death & Disease, Mar 18; 11(3):195. (SCIE) (IF: 5.638; SCIE ranking: 21.6%)
  • Chan MH, Hsieh MR, Liu RS, Wei DH, Hsiao M*, 2020, “Magnetically Guided Theranostics: Optimizing Magnetic Resonance Imaging with Sandwich-Like Kaolinite-Based Iron/Platinum Nanoparticles for Magnetic Fluid Hyperthermia and Chemotherapy”, Chemistry of Materials, 32(2) 697-708. (SCIE) (IF: 9.89; SCIE ranking: 10.2%,7.4%)
  • Huang WT, Chan MH, Chen X, Hsiao M*, Liu RS, 2020, “Theranostic Nanobubble Encapsulating A Plasmon-enhanced Upconversion Hybrid Nanosystem for Cancer Therapy”, Theranostics, Jan 1;10(2):782-796. (SCIE) (IF: 8.537; SCIE ranking: 6%)
  • Chiou J, Chang YC, Tsai HF, Lin YF, Huang MS, Yang CJ, Hsiao M*, 2019, “Follistatin-like protein 1 inhibits lung cancer metastasis by preventing proteolytic activation of osteopontin”, Cancer Research, 79(24),6113-6125. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Chang YC, Chiou J, Yang YF, Su CY, Lin YF, Yang CN, Lu PJ, Huang MS, Yang CJ, Hsiao M*, 2019, “Therapeutic targeting of aldolase A interactions inhibits lung cancer metastasis and prolongs survival”, Cancer Research, 79(18),4754-4766. (SCIE, SSCI) (IF: 9.13; SSCI ranking: 9.5%)
  • Chan MH, Liu RS, Hsiao M*, 2019, “Graphitic carbon nitride-based nanocomposites and their biological applications: a review.”, Nanoscale, 11(32),14993-15003, Cite 2. (SCIE) (IF: 7.233; SCIE ranking: 12.3%)
  • Jan YH, Lai TC, Yang CJ, Lin YF, Huang MS, Hsiao M*, 2019, “Adenylate kinase-4 modulates oxidative stress and stabilizes HIF-1α to drive lung adenocarcinoma metastasis”, Journal of Hematology and Oncology, 12(1):12, Cite 3. (SCIE) (IF: 6.35; SCIE ranking: 12%,10%)
  • Wang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, Ger LP, Chen YC, Lin FC, Hsiao M*, Lu PJ, 2018, “A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer”, Oncogene, 37(34), 4662-4678, Cite 14. (SCIE) (IF: 7.519; SCIE ranking: 9%,7.2%,14.7%,9.7%)
  • Chang YC, Yang YC, Tien CP, Yang CJ, Hsiao M*, 2018, “Roles of aldolase family genes in human cancers and diseases”, Trends in Endocrinology and Metabolism, Aug;29(8), 549-559, Cite 10. (SCIE) (IF: 10.893; SCIE ranking: 4.3%)
  • Chan MH, Pan YT, Chan YC, Hsiao M*, Chen CH, Sun L, Liu RS, 2018, “Nanobubble-embedded inorganic 808 nm excited-upconversion nanocomposites for tumorous multiple imaging and treatment”, Chemical Science, Feb 9; 9(12), 3141-3151, Cite 20. (SCIE) (IF: 8.668; SCIE ranking: 10.2%)
  • Chang YC, Chan YC, Chang MW, Lin YF, Yang CJ, Su CY, Huang MS, Wu AT, Hsiao M*, 2017, “Feedback regulation of ALDOA activates HIF-1α/MMP9 axis to promote lung cancer progression”, Cancer Letters, 403, 28-36, Cite 21. (SCIE) (IF: 6.375; SCIE ranking: 11.5%)
  • Lin TC, Hsiao M*, 2017, “Ghrelin and cancer progression”, Biochimica et Biophysica Acta-Reviews on Cancer, 1868, 51-57, Cite 23. (SCIE) (IF: 9.452; SCIE ranking: 6.2%,5.5%,6%)
  • Chang YC, Su CY, Chen MH, Chen WS, Chen CL, Hsiao M*, 2017, “Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promotes colon cancer metastasis and is associated with poor prognosis”, Molecular Cancer, 16(1), 135, Cite 12. (SCIE) (IF: 6.204; SCIE ranking: 12.4%,14.3%)
  • Chien MH, Lee WJ, Chang YC, Chang WM, Lai TC, Chan DV, Sharma R, Lin YF, Hsiao M*, 2017, “A Fas ligand (FasL)-fused humanized antibody against tumor-associated glycoprotein 72 (hcc49scFV-FasL) selectively exhibits the cytotoxic effect against oral cancer cells with a low FasL/Fas ratio”, Molecular Cancer Therapeutics, 16(6), 1102-1113, Cite 5. (SCIE) (IF: 5.764; SCIE ranking: 16.6%)
  • Chan MH, Pan YT, Lee IJ, Chen CW, Chan YC, Hsiao M*, Wang F, Sun L, Chen X, Liu RS, 2017, “Minimizing the heat effect of photodynamic therapy based on inorganic nanocomposites mediated by 808 nm near-infrared light”, Small, 13(21), 1700038, Cite 44. (SCIE) (IF: 8.643; SCIE ranking: 11.5%,7.3%,7.4%,14.9%,10.8%,11%)
  • Chang YC, Chi LH, Chang MW, Su CY, Lin YF, Chen CL, Chen MH, Chang PM, Wu AT, Hsiao M*, 2017, “Glucose transporter 4 promotes head and neck cancer metastasis through TRIM24-DDX58 axis”, Journal of Hematology & Oncology, 10(1), 11, Cite 10. (SCIE) (IF: 6.35; SCIE ranking: 12%,10%)
  • Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Lai TC, Wu GH, Hsu YM, Chi LH, Hsiao JR, Chen CL, Chang JY, Shieh YS, Hsiao M*, Shiah SG, 2016, “Dysregulation of Runx2/Activin A axis upon miR376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma.”, Cancer Research, 76(24),7140-7150, Cite 16. (SCIE) (IF: 9.122; SCIE ranking: 6.9%)
  • Chen CW, Chan YC, Hsiao M*, Liu RS, 2016, “Plasmon-enhanced photodynamic cancer therapy by upconversion nanoparticles conjugated with Au nanorods”, ACS Applied Materials & Interfaces, 8(47), 32108-32119, Cite 35. (SCIE) (IF: 7.504; SCIE ranking: 13.8%,8%)
  • Chan YC, Chen CW, Chan MH, Chang YC, Chang MW, Chi LH, Yu HM, Lin YF, Tsai DP, Liu RS, Hsiao M*, 2016, “MMP2-sensing up-conversion nanoparticle for fluorescence biosensing in head and neck cancer cells”, Biosensors & Bioelectronics, Jun 15;80:131-139, Cite 17. (SCIE) (IF: 7.78; SCIE ranking: 8.2%,5.6%,3.4%,2.6%,12.6%)
  • Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, Huang MS, Calkins MJ, Hsiao M*, Lu PJ, 2016, “Huntingtin-Interacting Protein-1 Is an Early-stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated EMT.”, American Journal of Respiratory and Critical Care Medicine, Apr 15;193(8):869-880, Cite 10. (SCIE) (IF: 13.204; SCIE ranking: 6.1%,3.4%)
  • Lin TC, Su CY, Lai TC, Pan WA, Jan YH, Yeh CT, Chen CL, Ger LP, Chang HT, Yang CJ, Huang MS, Shyy JY, Tsai MD, Hsiao M*, 2016, “NIFK promotes cancer metastasis through Runx1-dependent repression of casein kinase 1α to activate Wnt/b-catenin signaling”, eLife, Mar 17;5:e11288, Cite 15. (SCIE) (IF: 7.725; SCIE ranking: 4.7%)
  • Lin TC, Liu YP, Chan YC, Su CY, Lin YF, Hsu SL, Yang CS, Hsiao M*, 2015, “Ghrelin promotes renal cell carcinoma metastasis via snail activation and is associated with poor prognosis”, The Journal of Pathology, 237(1), 50-61. Cite 21. (SCIE) (IF: 6.253; SCIE ranking: 14.3%,6.3%)
  • Yang YF, Jan YH, Liu YP, Yang CJ, Su CY, Lin YF, Chang YC, Lai TC, Chiou J, Tsai HY, Lu J, Shen CN, Shew JY, Lu PJ, Huang MS, Hsiao M*, 2014, “Squalene Synthase Induces TNFR1 Enrichment in Lipid Rafts to Promote Lung Cancer Metastasis.”, American Journal of Respiratory and Critical Care Medicine, 190(6), 675-687. Cite 16. (SCIE) (IF: 15.239; SCIE ranking: 3.3%,6.1%)
  • Liu YP, Liao WC, Ger LP, Chen JC, Hsu TI, Lee YC, Chang HT, Chen YC, Jan YH, Lee KH, Zeng YH, Hsiao M*, Lu PJ, 2013, “Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer.”, Cancer Research, 73(20), 6194-6205. Cite 13. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Tsai HY, Yang YF, Wu AT, Yang CJ, Liu YP, Jan YH, Lee CH, Hsiao YW, Yeh CT, Shen CN, Lu PJ, Huang MS, Hsiao M*, 2013, “Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78.”, Oncogene, 32(41), 4921-4931. Cite 40. (SCIE) (IF: 6.854; SCIE ranking: 8.8%,11.3%,12.1%,16.8%)
  • Liu YP, Hsiao M*, 2013, “Exercise-induced SPARC prevents tumorigenesis of colon cancer”, Gut, 62(6), 810-811. Cite 7. (SCIE) (IF: 17.016; SCIE ranking: 3.8%)
  • Liu CH, Chen TC, Chau GY, Jan YH, Chen CH, Hsu CN, Lin KT, Juang YL, Lu PJ, Cheng HC, Chen MH, Chang CF, Ting YS, Kao CY, Hsiao M*, Huang CY, 2013, “An analysis of protein-protein interactions in cross-talk pathways reveals CRKL as a novel prognostic marker in hepatocellular carcinoma.”, Mol Cel Proteomics, 12(5), 1335-1349. Cite 22. (SCIE) (IF: 5.236; SCIE ranking: 11.4%)
  • Cheng LC, Chen HM, Lai TC, Liu RS, Sung JC, Hsiao M*, Chen CH, Her LJ, Tsai DP, 2013, “Targeting polymeric fluorescent nanodiamond-gold/silver multi-functional nanoparticles as a light-transforming hyperthermia reagent for cancer cell”, Nanoscale, May 7;5(9):3931-40. Cite 38. (SCIE) (IF: 7.233; SCIE ranking: 14.6%,19.6%,10.5%,10.3%)
  • Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M*, 2013, “Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling”, Cancer Research, 73(1), 406-416. Cite 129. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Jan YH, Tsai HY, Yang CJ, Huang MS, Yang YF, Lai TC, Lee CH, Jeng YM, Huang CY, Su JL, Chuang YJ, Hsiao M*, 2012, “Adenylate Kinase-4 Is a Marker of Poor Clinical Outcomes That Promotes Metastasis of Lung Cancer by Downregulating the Transcription Factor ATF3.”, Cancer Res, 72(19), 5119-5129. Cite 14. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M*, Lu PJ, 2012, “RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells.”, Oncogene, 31(39), 4302-4316. Cite 42. (SCIE) (IF: 6.854; SCIE ranking: 8.8%,11.3%,12.1%,16.8%)
  • Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M*, Tsou AP, 2012, “MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.”, Journal of Clinical Investigation, 122(8), 2884-2897. Cite 483. (SCIE) (IF: 13.251; SCIE ranking: 3%)
  • Cheng LC, Huang JH, Chen HM, lai TC, Liu RS, Hsiao M*, Chen CH, Her LJ, Tsai DP, 2012, “Seedless, silver-induced synthesis of star-shaped gold/silver bimetallic nanoparticles as high efficiency photothermal therapy reagent”, Journal of Materials Chemistry, 22(5), 2244-2253. Cite 129. (SCIE)
  • Hua KT, Tan CT, Johansson G, Lee JM, Yang PW, Lu HY, Chen CK, Su JL, Chen PB, Wu YL, Chi CC, Kao HJ, Shih HJ, Chen MW, Chien MH, Chen PS, Lee WJ, Cheng TY, Rosenberger G, Chai CY, Yang CJ, Huang MS, Lai TC, Chou TY, Hsiao M*, Kuo ML, 2011, “N-alpha-Acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity”, Cancer Cell, 19(2), 218-231. Cited 62. (SCIE) (IF: 22.844; SCIE ranking: 2.6%,3.1%)
  • Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH, Chien MH, Yang CJ, Huang MS, Hsiao M*, Kuo ML, 2010, “H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM.”, Cancer Research, 70(20), 7830-7840. Cite 201. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Cheng WH, Lu PJ, Ho WY, Tung CS, Cheng PW, Hsiao M*, Tseng CJ, 2010, “Angiotensin II Inhibits Neuronal Nitric Oxide Synthase Activation Through the ERK1/2-RSK Signaling Pathway to Modulate Central Control of Blood Pressure.”, Circulation Research, Mar 5;106(4):788-95. Cite 56. (SCIE) (IF: 15.211; SCIE ranking: 3.1%,1.4%,3.1%)
  • Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M*, Huang HD, Tsou AP, 2009, “MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.”, Hepatology, May; 49(5), 1571-1582. Cite 410. (SCIE) (IF: 14.079; SCIE ranking: 6.3%)
  • Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL, Horng JT, Hsiao M*, Tsou AP, 2008, “Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma.”, Oncogene, Sep 18;27(42):5578-5589. Cite 136. (SCIE) (IF: 6.854; SCIE ranking: 8.8%,11.3%,12.1%,16.8%)